Seven abstracts from across Jazz Pharmaceuticals plc’s neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April 5-9, 2025, in San Diego.
Sunosi contributed $93.8 million to Axsome’s full-year 2024 revenue as the company moves forward with AXS-12 regulatory plans.
A study suggests that a way to improve the salty taste of once-nightly sodium oxybate could be found in patients’ refrigerators.
An insomnia drug developer has been honored with The Pharmaceutical Society of Japan Award for Drug Research and Development 2024.
Read More
Rising deaths from pregabalin, also used for restless legs syndrome, spotlight the need for drug interaction knowledge to protect patients.
Read More
A new consumer update issued by the FDA cautions against the risks of complex sleep behaviors associated with prescription medications for insomnia, sometimes known as “Z-drugs.”
Read More
Sleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.
Read More
Doctors have discovered evidence pointing to a safer way to take benzodiazepines, which they say could reduce the risk of falls, hospitalizations, and deaths.
Read More
The review evaluated all high-sodium oxybates, fixed-dose, and twice-nightly administrations in both oxybate-experienced patients and those who had not undergone prior treatment.
Read More
Zevra Therapeutics highlighted the heart safety of serdexmethylphenidate, the main ingredient in KP1077, its potential treatment for idiopathic hypersomnia, during a poster presentation at Psych Congress 2023.
Read More
New findings suggest that treating insomnia can stop opioid-seeking behavior, even after ending treatment.
Read More
Researchers delve into the mechanism by which aripiprazole affects circadian rhythm sleep disorders, shedding light on its efficacy beyond psychiatric treatments.
Read More
One poster will feature results from the SHARP study, a trial of Sunosi in 59 patients with excessive daytime sleepiness associated with OSA and impaired cognitive function.
Read More
The United States Patent and Trademark Office has denied a Petition for Reexamination concerning a patent covering the active ingredient in Wakix (pitolisant).
Read More
During the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.
Read More
The agencies issued a joint statement updating the public on ongoing actions being taken to resolve the shortage of prescription stimulants, a drug class often used to treat narcolepsy.
Read More
Harmony Biosciences reported second-quarter business updates, showcasing an upswing in prescription demand for its narcolepsy drug, Wakix.
Read More
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients aged 7 and older with narcolepsy.
Read More